Previous close | 3.3900 |
Open | 3.3800 |
Bid | 3.1800 x 1100 |
Ask | 3.2700 x 1000 |
Day's range | 3.1400 - 3.4799 |
52-week range | 1.7950 - 4.5000 |
Volume | |
Avg. volume | 894,569 |
Market cap | 417.572M |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | 45.43 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The company said it learned that its products will again be covered by three Medicare Administrative Contractors.
Shares of Organogenesis Holdings (NASDAQ: ORGO) were down more than 19% as of 11 a.m. on Thursday after the company announced second-quarter earnings and withdrew annual guidance after the markets closed on Wednesday. Organogenesis is a healthcare company that makes advanced care products for the wound-healing process. The company operates in two segments, Advanced Wound Care and Surgical & Sports Medicine, and both saw declines.
ORGO earnings call for the period ending June 30, 2023.